Sudeep Pharma Share Price, IPO Listing Highlights: Sudeep Pharma is set to finalise its share allotment today, after three days of subscription. The Rs 895 crore initial public offering (IPO) was between November 21-25.
Sudeep Pharma IPO: Subscription recap
On the final day of bidding, the IPO saw applications for more than 99 crore shares, far more than the 1.05 crore shares available. This resulted in an overall subscription of 93.71 times, according to data from the National Stock Exchange (NSE).
Retail investors subscribed their portion 15.65 times, while the Non-Institutional Investors (NIIs), who typically include high-net-worth individuals, submitted bids worth 116.72 times their quota. The Qualified Institutional Buyers (QIBs) received a subscription of 213.08 times.
| Sudeep Pharma IPO | Key Details |
| Price bnfnd | Rs 563-593 per share |
| Subscription | 93.71 times |
| GMP | 14.67% |
| IPO Allotment date | November 26 |
| Listing date | November 28 |
Sudeep Pharma IPO: Grey market trend
Ahead of the listing, Sudeep Pharma’s unlisted shares have been actively traded in the grey market. The stock is currently quoted around Rs 680, which indicates a grey market premium (GMP) of about 14.67% over the IPO’s upper price band of Rs 593.
What Sudeep Pharma does
The company is involved in the manufacturing of pharmaceutical excipients and speciality ingredients, which are essential components used in medicines. Furthermore, it operates six manufacturing plants. It produces mineral-based ingredients such as calcium, magnesium, iron, zinc, sodium and potassium.
Sudeep Pharma IPO Allotment Status Highlights: Follow Live Coverage on Sudeep Pharma IPO GMP, Allotment Status, Grey Market Premium, Listing Date, Review and More
Sudeep Pharma IPO Allotment Status, GMP Live: About the company
Sudeep Pharma, established in 1989, is a technology-led manufacturer of excipients and speciality ingredients serving the pharmaceutical, food, and nutrition industries. With a global footprint spanning the U.S., South America, Europe, the Middle East, Africa, and Asia-Pacific.
Sudeep Pharma operates 3 manufacturing units across the country, running at 46% capacity utilisation in FY25—indicating significant headroom to increase topline as utilisation picks up. The 3-year average RoE is healthy at 36% (FY23-25), indicating capital efficiency, along with a comfortable debt-to-equity ratio at 0.2x in FY25.
Sudeep Pharma IPO Allotment Status, GMP Live: Geojit Investments on IPO valuation
"At the upper price band of Rs 593, Sudeep Pharma is available at a P/E of 48x (FY25 diluted basis), which appears to be fairly priced. The company is well-positioned for sustained long-term growth, supported by robust operational performance, the NSS acquisition that strengthens its European footprint in infant nutrition and formulations, and its planned foray into the high-growth battery-grade minerals segment," said Geojit Investments in an IPO note.
Sudeep Pharma IPO Allotment Status, GMP Live: Net profit and margin growth
Sudeep Pharma over FY23–FY25, posted a revenue growth of 8%, EBITDA of 46%, and net profit of 49% CAGR, driven by a favourable business mix and improving operating leverage. The company has been rapidly expanding its high-margin speciality ingredients segment, which contributed 34% to revenue in Q1FY26 compared to 17% in FY22.
Sudeep Pharma IPO Allotment Status, GMP Live: Strong and sticky clientele
Sudeep Pharama serves over 1,100 customers- including Pfizer, Intas, Mankind, Aurobindo, Alembic, Merck and Danone- with an average relationship tenure of more than seven years, reflecting strong customer stickiness and sustained revenue visibility.
Sudeep Pharma IPO Allotment Status, GMP Live: Industry growth
The global pharmaceutical excipients and speciality food ingredients market together are projected to grow steadily, with excipients rising from $10.4 billion in 2024 to about $13 billion by 2029 (CAGR 4.7%), and speciality food ingredients expanding from $85 billion in 2024 to $118 billion by 2029 (CAGR 6.8%).
Sudeep Pharma IPO Allotment Status, GMP Live: Manufacturing units
Sudeep Pharma currently operates six manufacturing facilities with a combined annual capacity of around 50,000 MT. The company also has a presence in Europe through a strategic production unit.
Sudeep Pharma IPO Allotment Status, GMP Live: Share distribution
The share distribution followed the standard structure, with 50% reserved for Qualified Institutional Buyers (QIBs), 15% allocated to Non-Institutional Investors (NIIs), and 35% earmarked for Retail Individual Investors (RIIs). Additionally, anchor investors received 30% of the total shares offered to institutional investors.
Sudeep Pharma IPO Allotment Status, GMP Live: R&D focus
Sudeep Pharma operates dedicated in-house laboratories and pilot-scale facilities that drive innovation in mineral salts and excipient formulations. Its research and development efforts cater to both the pharmaceutical and food industries. The company’s portfolio includes excipients based on calcium, magnesium, iron, zinc, sodium, and potassium, which are widely used in tablets, capsules, processed foods, beverages, and nutritional supplements.
Sudeep Pharma IPO Allotment Status, GMP Live: Presence in global market
Sudeep Pharma supplies ingredients to more than 60 countries. The European facility has helped widen its access to international clients across healthcare and food sectors.
Sudeep Pharma IPO Allotment Status, GMP Live: About the company
Founded in 1989, Sudeep Pharma is a leading player in the pharmaceutical ingredients industry. Headquartered in Vadodara, Gujarat, the company operates several manufacturing facilities across the region.
Sudeep Pharma IPO Allotment Status, GMP Live: How will the money be used?
A portion of the public issue comprises fresh equity shares issued by the company. The proceeds from this segment will primarily fund capital expenditure, including the purchase of new machinery for the production line at the company’s Nandesari Facility 1 in Gujarat. The remaining funds will be allocated for general corporate purposes.
Sudeep Pharma IPO Allotment Status, GMP Live: IPO proceeds
The company plans to use Rs 75.8 crore from the fresh issue towards capital expenditure for procuring machinery for its production line at the Nandesari Facility 1 in Gujarat, with the remaining funds allocated toward general corporate purposes.
The IPO opened for subscription on November 21, 2025, and will remain open until November 25, 2025. The allotment is expected on November 26, 2025, and the company is likely to list on the BSE and NSE on November 28, 2025. The price band for the issue has been set at Rs 563–Rs 593 per share.
Sudeep Pharma IPO Allotment Status, GMP Live: Step-by-step guide on how to check alottment
Step 1: Visit the official website of the BSE or click on the direct link - bseindia.com/investors/appli_check.aspx.
Step 2: Select 'Equity' under 'Issue Type'
Step 3: Select 'Issue Name' (Sudeep Pharma IPO in this case).
Step 4: Provide all details, like the application number or PAN, to proceed further.
Step 5: Click 'submit'.
The status of your Sudeep Pharma IPO allotment will appear on the screen.
Sudeep Pharma IPO Allotment Status, GMP Live: Checking through the registrar’s website
Sudeep Pharma’s IPO registrar, MUFG Intime, offers another reliable option.
On the registrar’s portal, choose Sudeep Pharma from the list and provide the relevant identification – this could be your PAN, application number, demat account ID (DP ID/Client ID), or your bank account number linked to the IPO application.
Sudeep Pharma IPO Allotment Status, GMP Live: Allocation breakdown
The share distribution followed the standard structure:
50% reserved for Qualified Institutional Buyers (QIBs)
15% for Non-Institutional Investors (NIIs)
35% for Retail Individual Investors (RIIs)
Anchor investors were allotted 30% of the total shares offered to institutions.
Sudeep Pharma IPO Allotment Status, GMP Live: Structure and pricing
The IPO was sized at Rs 895 crore, comprising a Rs 95 crore fresh issue and an Rs 800 crore offer for sale by existing shareholders.
The price band was fixed at Rs 563–Rs 593 per share.
A total of Rs 268.5 crore was raised from anchor investors ahead of the issue opening.
Sudeep Pharma IPO Allotment Status, GMP Live: Global market reach
Sudeep Pharma supplies ingredients to more than 60 countries. The European facility has helped widen its access to international clients across healthcare and food sectors.
Sudeep Pharma IPO Allotment Status, GMP Live: Research & Development setup and product portfolio
The firm has in-house laboratories and pilot-scale units that work on developing and improving mineral salts and excipient formulations. The R&D centres support both its pharma and food segments.
Its offerings include calcium, magnesium, iron, zinc, sodium, and potassium-based excipients. These products are used in tablets, capsules, processed foods, beverages, and nutritional supplements.
Sudeep Pharma IPO Allotment Status, GMP Live: Manufacturing footprint
Sudeep Pharma currently operates six manufacturing facilities with a combined annual capacity of around 50,000 MT. The company also has a presence in Europe through a strategic production unit.
Sudeep Pharma IPO Allotment Status, GMP Live: Use of fresh issue funds
Proceeds of around Rs 75.81 crore from the fresh issue will be used to purchase machinery for the Nandesari Facility I in Gujarat and for general corporate needs.
Sudeep Pharma IPO Allotment Status, GMP Live: Listing timeline
The company’s shares are scheduled to list on NSE and BSE on November 28, 2025. Allotment information is available on the BSE, NSE, and MUFG Intime India websites.
Sudeep Pharma IPO Allotment Status, GMP Live: Allocation breakdown
The share distribution followed the standard structure:
50% reserved for Qualified Institutional Buyers (QIBs)
15% for Non-Institutional Investors (NIIs)
35% for Retail Individual Investors (RIIs)
Anchor investors were allotted 30% of the total shares offered to institutions.
Sudeep Pharma IPO Allotment Status, GMP Live: Core operations
The company manufactures excipients and mineral-based ingredients used in medicines, food, and nutrition products. Its portfolio covers more than 200 items supplied to various industries.
Sudeep Pharma IPO Allotment Status, GMP Live: Company background
Established in 1989, Sudeep Pharma operates in the pharmaceutical ingredients space. The company is based in Vadodara, Gujarat, and runs multiple production facilities across the region.
Sudeep Pharma IPO Allotment Status, GMP Live: Checking through the registrar’s website
Sudeep Pharma’s IPO registrar, MUFG Intime, offers another reliable option.
On the registrar’s portal, choose Sudeep Pharma from the list and provide the relevant identification - this could be your PAN, application number, demat account ID (DP ID/Client ID), or your bank account number linked to the IPO application.
Sudeep Pharma IPO Allotment Status, GMP Live: Checking on the NSE website
The National Stock Exchange also allows applicants to track their IPO applications.
Visit the section that displays bid details for equity and SME offers.
After selecting Sudeep Pharma from the available issues, submit the required details such as your PAN and application number. The page will then show whether the shares have been allotted to you.
Sudeep Pharma IPO Allotment Status, GMP Live: IPO GMP trending higher
The GMP for the Sudeep Pharma IPO is up 14%. This indicates that the issue may list at a premium. However, readers must remember that the GMP is an unofficial metric and the actual listing price could be very different.
Sudeep Pharma IPO Allotment Status, GMP Live: Checking through the BSE website
Investors can verify their allotment status directly on the official BSE portal.
Once you open the page meant for IPO allotments, select the option for equity issues and look for Sudeep Pharma in the drop-down list.
You can proceed by entering either your application number or your Permanent Account Number (PAN).
After confirming the captcha, the system displays the status linked to your application.